How to get rid of lumps and bumps on face treatment

How to get rid of a bubble in your ear lobe use

Treating bacterial eye infections episcleritis,how to get rid of flu head congestion lightheadedness,how to get rid of old scars home remedies zits,what helps get rid of a sickness bug last - Step 1

A composition for treatment of bacterial infections of the eye is disclosed which comprises a lytic enzyme composition specific for the infecting bacteria, and a carrier for delivering said lytic enzyme. K H Nasibulini et al, RU-2103991, Composition for treating streptococcal diseases—comprises purified concentrate of streptococcal bacteriophage, solution of quinsosol, dry lanolin, albumin and vegetable oil, XP-002141110. LD Demidova et al, RU2064299, Cattle mastitis therapeutic preparation—comprises lyso: amidase of specific lytic activity and mono- and di-basic sodium phosphate(s), XP-002141111.
Babenko et al Enzymatic lysis of staphylococci in relation to their species and strain properties, 1990, Database Medline Online, US National Library of Medicine, Bethesda, MD, US, Database Accession No. Bartell, et al , Origin of polysaccharide depolymerase associated with bacteriophage infection, Journal of Virology, Mar.
Behnke, et al , Cloning and expression in Escherichia coli, Bacillus subtilis and Streptococcus sanguis of a gene for staphylokinase—a bacterial plasminogen activator, Mol Gen Genet.
Bessen, et al , Chemical characterization of binding properties of opacity-associated protein II from Neissena gonorrheae, infection and immunity, Jan. Biziulevichius, et al , In vivo studies on lysosubtilin 3 Efficacy for treatment of mastitis and superficial lesions of the udder and teats in cows.
Boizet, et al , Cloning, expression and sequence analysis of an endolysin-encoding gene of Lactobacillus bulgaricus bacteriophage mol. Caldwell, et al , Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis, Infection and Immunity, Mar. Corbel, et al , Soluble antigens obtained from influenza virus by treatment with non-ionic detergent, J Hyg .Camb , 1970, pp 81-96, vol. Croux, et al , Interchange of functional domains switches enzymes specificity construction of a chimeric pneumococcal-clostndial cell wall lytic enzyme, Molecular Microbiology, 1993, pp 1019-25, vol. Diaz et al , Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits, Journal of Biological Chemistry, Mar. Dikon, et al , Lysostaphin an enzymatic approach to stapylococcal disease, III Combined lysostaphin-methicilin therapy of established staphylococcal abcesses in mice, The Yale Journal of Biology and Medicine, Aug. Fischetti, et al , Size variation of the M protein in group A streptococci, Journal of Exp Med , Jun. Garcia, et al , Bacteriophages of Streptococcus pneumoniae A molecular approach, Microbial Drug Resistance, Summer 1997, pp 165-176, vol.
Garcia, et al , Cloning, purification and bichemical characterization of the pneumococcal bacteriophage Cp-1 lysin, Journal of Virology, Aug.
Garcia, et al , Modular organization of the lytic enzymes of streptococcus and its bacteriophages, Gene, 1990, pp 81-88, vol.
Gerardy-Schann, et al , Molecular cloning and functional expression of bacteriophage PK1E-encoded endoneuraminidase Endo NE, Molecular Microbiology, May 1995, pp 441-450, vol.
Harrison, et al , Therapeutic activity of lysostaphin in experimental staphylococcal infections.
Hayashi, et al , Effects of N-Acet.Imuramidase from Streptomyces rutgersensis H-46 as a food preservative.
Hayashida, et al , Further characterization of PL-1 phage associated N-acetylmuramidase of Lactobacillus casei, Journal of General Microbiology, May 1987, pp 1343-1349, vol. Higuchi, et al , Transfection of streptococcus sanguis by phage deoxyribonucleic acid isolated from streptococcus mutans, infection and immunity, Mar. Huan, et al, Methicillin-resistant staphylococcus aureus infection and its treatment in burned patients, Chinese Journal of Surgery, 1994, vol. Hughey, et al , Antimicrobial activity of lysozome against bacteria involved in food spoilage and food-borne disease. Kohler, Systemic therapy with aerosols Aerosols in Medicine Principles, Diagnosis and Therapy, 1993, Elseveir Science Publishers, pp 303-319. Lawman, et al , Molecular cloning of the extracellular endodextranase of streptococcus salivanus, Journal of Bacteriology, Dec.
Loessner, et al , Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of staphylococcus aureus bacteriophage 187, Journal of Bacteriology, Aug. Loessner, et al , Modified listeria bacteriophage lysin genes (ply) allow efficient overexpression and one—step purification of biochemically active fusion proteins. Lopez, et al , Architecture and domain interchange of the pneumococcal cell wall lytic enzymes, Genetics of Streptococci, Enterococci and Lactococci, Developments in Biological Standardization 1995 pp 273-281 vol.
Lopez, et al , The pneumococcal cell wall degrading enzymes a modular design to create new lysins, Microbial Drug Resistance, Nov.
Martin, et al , Functional analysis of the two-gene lysis system of the penumococcal phage Cp-1 in homologous and heterologous host cells, Journal of Bacteriology, Jan. Mukhlis et al , Characterization and Immunogenicity of HSV-1 antigens obtained following zwitteronic detergent treatment, Vaccine, Sep. Nelson, et al , Prevention and elim nation of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme, PNAS, Mar. Nelson, et al , Selective and rapid killing of group A streptococci using a muralytic enzyme. Oki, et al , Functional and structural features of the holin HOL protein of the Lactobacillus plantarum phage analysis in escherichia coli system, Gene, 1997, pp 137-145, vol. Okuhara, et al , Preparation of group A streptococcal cell membranes by treatment with group C streptococcus phage—associated lysin, Annales Paediatrici Japonici. Patton, et al , Routes of delivery case studies, Pulmonary delivery of peptides and proteins for systemic action, Advanced Drug Delivery Reviews, 1992, pp 179-196, vol. Polak, et al , In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant staphylococcus aureus, Diagn Microbiol Infect Dis , 1993, pp 265-270, vol. Raina, Purification of streptococcus group C bacteriophage lysin Journal of Bacteriology, Jan. Ronda, et al, Infection of streptococcus oralis NCTC 11427 by pnueomococcal phages, FEMS Microbiology Letters, 1989, pp 187-192, vol. Sanz, et al , Construction of a multifunctional pneumococcal murein hydrolase by module assembly, Eur J Biochem , Feb.
Sato, et al, Partial characterization of n—Butanol—solubilized rejection—type antigens of syngeneic murine colon tumors, JNCI, Apr. Sheehan, et al , Analysis of the catylytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling, FEMS Microbiology Letters, 1996, pp 23-28, vol. Sheehan, et al , The lytic enzyme of the pneumococcal phage Dp-1 A chimeric lysin of intergeneric origin, Molecular Microbiology, 1997, pp 717-725. Witte, et al , Characterization of escherichia coli lysis using a family of chimeric E-L genes. Yarnall, et al, Isolation and partial characterization of a type II Fc receptor from a group A streptococcus, Molecular and Cellular Biochemistry, 1986, pp 57-66, vol. Cisani, et al , High-level potentiation of lysostaphin anti-stapylococcal activity by lysozyme, Antimicrobial Agents and Chemotherapy, Apr. Get actionable intelligence on medical innovation at MedCity CONVERGE July 12-13 in Philly.
Overcoming challenges posed by the growing number of infections that are resistant to traditional antibiotics is the goal of a startup surfacing today with a $3 million Series A and a drug development partnership with Roche.
Spero Therapeutics was born last year out of a collaboration between VC firm Atlas Venture’s seed program and Partners Innovation Fund, the strategic venture fund for Partners HealthCare.
The company’s lead product takes aim at treating acute bacterial infections and preventing chronic persistence of infections caused by gram-negative bacteria, like pneumonia, bloodstream infections, or wound or surgical site infections.
Persistence: Many bacteria can adopt a state of persistence, in which they tolerate existing antibiotics, promoting deadly chronic infections. Initial funding came from Atlas, Partners Innovation Fund and SR One, the corporate venture arm of GlaxoSmithKline, the company said in its announcement today. Roche is also providing non-dilutive R&D funding in exchange for the option to acquire the lead program at the IND-application phase. Atlas Venture’s Bruce Booth put some context around this option-to-buy deal structure in a blog post today. Derrickson defended a recent, controversial study about teledermatology and its methodology, noting that “our clients regularly secret-shop us,” and he predicted more of the same was coming. Apply now to join the TMCx accelerator’s medical device cohort and collaborate with the nation’s best hospitals. The carrier for delivering at least one lytic enzyme to the eye may be but is not limited to the use of an isotonic solution.
Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US and abstracts of the General Meeting of the American Society for Microbiology, 2000, pp 32-33. The method according to claim 1, wherein said carrier is selected from the group consisting of candy, chewing gum, lozenge, troche, tablet, powder, aerosol, liquid and liquid spray. The method according to claim 1, wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt. The method according to claim 1, further comprising a bactericidal or bacteriostatic agent as a preservative.
The method according claim 1, comprising administering a concentration of about 100 to about 500,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passage. The method according to claim 1, comprising administering the concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passage.
Field of the InventionThe present invention discloses a method and composition for the treatment of bacterial infections by the use of a lysing enzyme blended with an appropriate carrier suitable for the treatment of the infection.2.
It’s based on the work of Laurence Rahme, a microbiologist at Massachusetts General Hospital and associate professor of surgery at Harvard Medical School. After abandoning development of antibiotics a decade and a half ago, Roche has recently been dipping its toes back in through drug development deals with Switzerland’s Polyphor and UK-based Discuva. Participants receive premium work space, access to Texas Medical Center clinicians and corporate partners, and industry-led curriculum from prototype development to V&V.
Description of the Prior ArtIn the past, antibiotics have been used to treat various infections.
Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.
Physicians might consider that Morgellons and Bartonella are in some way intertwined.??Morgellons sufferers report an array of symptoms happening just under the skin, such as the emergence of fibers and filament clusters, specks, particles and sand shaped granules, yet physicians are unaware of this phenomena because they are not using enlargement devices.
An unaided visual exam using the naked eye is no longer appropriate to an emerging illness involving so many artifacts. Fleming's discovery of penicillin, as well as the work of numerous others in the field of antibiotics, are well known.

No one trusts the judgment of a mechanic who refuses to look under the hood of a car. A more thorough approach needs to be taken using equipment such as dermascopes and microscopes, as this is the only way to identify the microscopic fibers that are the defining symptom of Morgellons, and which separates it from all other diseases. Over the years, there have been additions and chemical modifications to the “basic”antibiotics in attempts to make them more powerful, or to treat people allergic to these antibiotics.Others have found new uses for these antibiotics. Using a dermascope can also prevent misdiagnosing diseases that have some similar symptoms, such as Lyme (although some patients may have both). Microscopic enlargement needs to be at minimum 60x-200x in order to see the fibers clearly. As evidenced in the photos in our galleries, there is something clearly wrong with the skin of Morgellons sufferers. Most doctors currently believe that the fibers patients come to see them about are 'textile' in nature. If you take a look at the galleries of fibers in urine, stool, blood, skin, and hair, you will see that these filaments are invading the body systemically and cannot possibly be textile.
The method and composition for topically treating acne and acneiform dermal disorders includes applying an amount of an antibiotic selected from the group consisting of ampicillin, amoxicillin, other aminopenicillins, and cephalosporins, and derivatives and analogs thereof, effective to treat the acne and acneiform dermal disorders.
Click here to view other particles in the skin as well as other unidentified artifacts.?• ?Randy Wymore, Director of OSU-CHS Center for the Investigation of Morgellons Disease and Associate Professor of Pharmacology and Physiology had the fibers analyzed at the Tulsa police department's forensic laboratory. The Morgellons particles didn't match any of the 800 fibers on their database, nor the 85,000 known organic compounds. Larger doses of stronger antibiotics are now being used to treat ever more resistant strains of bacteria.
For those insisting the CDC study of Morgellons laid down the law for definitive answers about Morgellons, I'd suggest you listen to Doctor Randy Wymore speak more in depth about the study and its inherent flaws and bias. The use of more antibiotics and the number of bacteria showing resistance has led to increasing the amount of time that the antibiotics need to be used. Many clinicians refer to this condition as delusional parasitosis or delusional infestation and consider the filaments to be introduced textile fibers. Broad, non-specific antibiotics, some of which have detrimental effects on the patient, are now being used more frequently. In contrast, recent studies indicate that MD is a true somatic illness associated with tickborne infection, that the filaments are keratin and collagen in composition and that they result from proliferation and activation of keratinocytes and fibroblasts in the skin.
Previously, spirochetes have been detected in the dermatological specimens from four MD patients, thus providing evidence of an infectious process. (2013) has revealed the presence of Borrelia in Morgellons lesions in everyone tested.
It is the subject of considerable debate within the medical profession and is often labeled as delusions of parasitosis or dermatitis artefacta.
This view is challenged by recent published scientific data put forward between 2011-2013 identifying the filaments found in MD as keratin and collagen based and furthermore associated with spirochetal infection. The novel model of the dermopathy put forward by those authors is further described and, in particular, presented as a dermal manifestation of the multi-system disease complex borreliosis otherwise called Lyme disease. The requirements for a diagnosis of delusional disorder from a psychiatric perspective are clarified and the psychological or psychiatric co-morbidity that can be found with MD cases is presented. 4,957,686 (Norris) discloses a procedure of improved dental hygiene which comprises introducing into the mouth bacteriophages parasitic to bacteria which possess the property of readily adhering to the salivary pellicle.It is to be noted that the direct introduction of bacteriophages into an animal to prevent or fight diseases has certain drawbacks. Management of the multisytem disease complex is discussed both in general and from a dermatological perspective. Additionally, there must be the right number of phages to attach to the bacteria; if there are too many or too few phages, there will either be no attachment or no production of the lysing enzyme. The phages are also inhibited by many things including bacterial debris from the organism it is going to attack. 5,604,109 (Fischetti et al.) relates to the rapid detection of Group A Streptococci in clinical specimens, through the enzymatic digestion by a semi-purified Group C streptococcal phage associated lysin enzyme.
Despite evidence demonstrating that an infectious process is involved and that lesions are not self-inflicted, many medical practitioners continue to claim that this illness is delusional. We present relevant clinical observations combined with chemical and light microscopic studies of material collected from three patients with Morgellons disease.
Our study demonstrates that Morgellons disease is not delusional and that skin lesions with unusual fibers are not self-inflicted or psychogenic. Proliferative stages of bovine digital dermatitis demonstrate keratin filament formation in skin above the hooves in affected animals. The multifactorial etiology of digital dermatitis is not well understood, but spirochetes and other coinfecting microorganisms have been implicated in the pathogenesis of this veterinary illness. Morgellons disease is an emerging human dermopathy characterized by the presence of filamentous fibers of undetermined composition, both in lesions and subdermally. While the etiology of Morgellons disease is unknown, there is serological and clinical evidence linking this phenomenon to Lyme borreliosis and coinfecting tick-borne agents. Although the microscopy of Morgellons filaments has been described in the medical literature, the structure and pathogenesis of these fibers is poorly understood. In contrast, most microscopy of digital dermatitis has focused on associated pathogens and histology rather than the morphology of late-stage filamentous fibers. The most effective antibiotics have included tetracyclines (doxycycline, minocycline), macrolides (Zithromax, Biaxin), Septra DS, and quinolone drugs (Cipro, Levaquin, Avelox, and Factive). Often the skin lesions and associated symptoms resolve once the above antibiotics are used in a comprehensive treatment plan" ??Horowitz, Richard (2013-11-12). Why Can't I Get Better?: Solving the Mystery of Lyme and Chronic Disease (Kindle Locations 2662-2666). Some recent evidence suggests that the phage enzyme that lyses the Streptococcus organism may actually be a bacterial enzyme that is used to construct the cell wall and the phage. While replicating in the bacterium, a phage gene product may cause the upregulation or derepression of bacterial enzyme for the purpose of releasing the bacteriophage. These bacterial enzymes may be tightly regulated by the bacterial cell and are used by the bacteria for the construction and assembly of the cell wall.The use of these lytic enzymes for the prophylactic and therapeutic treatment of bacterial diseases, however, has not been explored, except by the inventors of the present invention.
Consequently, the present invention discloses the extraction and use of a variety of bacterial phage associated lytic enzymes for the treatment of a wide variety of illnesses caused by bacterial infections.The use of phage associated lytic enzymes produced by the infection of a bacteria with a bacteria specific phage has numerous advantages for the treatment of diseases. Still, 100% of the patients, that were felt to genuinely haveMorgellons Disease, have large microscopic-to small macroscopic fibersvisible under their outer layer of skin. As the phage are targeted for specific bacteria, the lytic enzymes do not interfere with normal flora. These fibers are not associated withscabs or open lesions, nor are they under scarred tissue. Also, lytic phages primarily attack cell wall structures which are not affected by plasmid variation.
The idea thatMorgellons fibers are mere fuzz and lint, simply sticking to the lesions andscabs, is not possible based on the observations that were just described.These fibers are under "normal-appearing" areas of skin. The photographs indicate that the particles are very active, and are growing "tendrils," fibers," "ruffles," protrusions," and are creating connections between themselves. These connecting "fibers" appear to be creating translucent "crystal clear" objects that give the appearance of "crystal fibers."                                                                              —Fungihomeworld. 5,604,109 in its entirety by reference) uses an enzyme produced by the bacterial organism after being infected with a particular bacteriophage as either a prophylactic treatment for preventing those who have been exposed to others who have the symptoms of an infection from getting sick, or as a therapeutic treatment for those who have already become ill from the infection. 5mar2010                 ?                   ?        Although Morgellons has no known "cure" at this time, we believe recognizing and identifying the disease gives a patient something to go on so they can start becoming proactive with their health. The present invention is based upon the discovery that phage lytic enzymes specific for bacteria infected with a specific phage can effectively and efficiently break down the cell wall of the bacterium in question. At the same time, in most if not all cases, the semipurified enzyme is lacking in mammalian cell receptors and therefore is non-destructive to mammalian proteins and tissues when present during the digestion of the bacterial cell wall. Often these visits are out-of-pocket expenditures as patients escalate up the food chain to specialists not within their health plans, bankrupting themselves unnecessarily.
Having a diagnosis will allow sufferers to make informed decisions about their next healthcare choices. There is no silver bullet when it comes to Morgellons.
A holistic approach working with diet and pH, plus supplements to rebuild the body's systems is one avenue towards proactive change and symptom reduction. Fibers and particles in various states of emergence from the skin. This mass exodus happens after coconut oil has been applied to my skin and usually takes 3-4 hours after application to see these kind of results.
5,604,109 may be used to manufacture other lytic enzymes produced by bacteria infected with a bacteriophage specific for that bacteria. Depending on the bacteria, there may be variations in the growth media and conditions.In one embodiment of the invention, the prophylactic and therapeutic treatment of a variety of illnesses caused by Streptococcal pneumoniae, Streptococcus fasciae, and Hemophilus influenza are disclosed. Fibers under the skin can clearly be seen in these photos as well as in urine and stool, plus the lab doing DNA testing has noted that they are seeing fibers in stool samples. In another embodiment of the invention, gram negative bacterial infections caused by Listeria, Salmonella, E. I truly do not understand how this could be misconstrued as a mental illness—and anti-depressants and anti-psychotics are not a fix. This community is looking for a way to repair the health of the body.  A quick Google search revealed that only a quarter of the dermatologists in the United States even own a dermascope. These and other bacteria, which can infect the digestive system, can be treated by incorporating the lytic enzymes in suppository enemas, in syrups, or in other carriers to go directly to the site of the infection(s).In another embodiment of the invention, lytic enzymes are incorporated into bandages to prevent or treat infections of burns and wounds.
Plus, a scope that only enlarges 10 or 15 times, is not going to be appropriate for diagnosis of Morgellons. In yet another embodiment of the invention, the lytic enzymes of phage associated with Staphylococcus or Pseudomonas are incorporated into bandages to prevent or treat infections of burns and wounds.Vaginal infections caused by Group B Streptococcus can cause premature births and subsequent complications resulting in neonatal sepsis. The fact that our doctors are supposedly experts and authorities, and considered the last word in the eyes of most of the public, yet are clearly not equipped to diagnose a new disease such as Morgellons, reflects poorly on the medical profession.?You have power to move the Morgellons cause along, if only you will participate. We need your support and input as health "authorities" to bring credibility to the phenomenon? happening. Treatment with lytic enzymes are faster and more expedient than with antibiotics.In yet another embodiment of the invention the phage associated lytic enzyme is put into a carrier which is placed in an inhaler to treat or prevent the spread of diseases localized in the mucus lining of the oral cavity and lungs. If you think there are not enough people sick with this disease to warrant your time, think again and heed a call from those of us who are looking at the skin of our friends and families and are finding fibers in them. As of yet, this "healthy" population is asymptomatic, but we believe they are carrying the seeds of this disease in their systems. In another embodiment of the invention, the lytic enzyme would be administered in an aqueous form.
In yet another embodiment of the invention, lysostaphin, the enzyme which lyses Staphylococcus aureus can be included in the therapeutic agent.
In a further embodiment of the invention, conventional antibiotics may be included in the therapeutic agent with the lytic enzyme, and with or without the presence of lysostaphin. More than one lytic enzyme may also be included in the prophylactic or therapeutic agent.BRIEF DESCRIPTION OF THE DRAWINGFIG.

Imagine a world in which every patient going for a physical with their GP or dermatologist had 3 minutes devoted to examination of the skin with a scope—and what kind of data could be gathered from this! 1 is an electron micrograph of group A streptococci treated with lysin showing the collapse of the cell wall and the cell contents pouring out.DETAILED DESCRIPTION OF THE INVENTIONThe method for treating bacterial infections comprises treating the infection with a therapeutic agent comprising an effective amount of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for the bacteria.
That's the kind of world I would like to live in. One final note before I step off my soapbox is to reinforce the oath you took on becoming a doctor. The lytic enzyme is preferably in an environment having a pH which allows for activity of the lytic enzyme.The lytic enzyme can be used for the treatment or prevention of Hemophilus influenza, Pseudomonas, Streptococcus pneumoniae, Streptococcus fasciae, Streptococcus group B, Listeria, Salmonella, E.
DOP in patients records have led to loss of their legal rights, hospitalization against their will and in some cases children being removed from their parents.
It is preferred that the lytic enzyme is in an environment having a pH which allows for activity of the lytic enzyme.
If an individual has been exposed to someone with the upper respiratory disorder, the lytic enzyme will reside in the mucosal lining and prevent any colonization of the infecting bacteria.Two examples of bacteria which infect the upper respiratory system are Streptococcus pneumoniae and Hemophilus influenzae. In recent years, there has been an increase in the number of people, particularly children and the elderly, that are infected or are carriers of penicillin resistant Streptococcus pneumoniae and Hemophilus. While these bacteria are normally harmless residents of the host, they are opportunistic organisms that are able to cause infections when the resistance of the host has been compromised. By eliminating or reducing the number of these organisms in the upper respiratory tract, there will be a commensurate reduction in the number of infections by these bacteria.Infection of the Hemophilus bacteria by Bacteriophage HP 1 (a member of the P2-like phage family with strong similarities to coliphages P2 and 186, and some similarity to the retronphage Ec67) produces a lytic enzyme capable of lysing the bacteria.
Also, be cautious as to how you phase things as in "I'm having crawling sensations on my skin." instead of "I'm infested with bugs!" I'd refrain from using the term "Morgellons" until you sense you can trust your practitioner. The lytic enzyme for Streptococcus pneumoniae, previously identified as an N-acetyl-muramoyl-L-alanine amidase, is produced by the infecting Streptococcus pneumoniae with the Pal bacteriophage.
The therapeutic agent can contain either or both of the lytic enzymes produced by these two bacteria, and may contain other lytic enzymes for other bacteria. Click the links to see extensive documentation of Morgellons fibers in Urine, Stool, Blood, Skin, Hair Above: Fiber is magnified 200x. The composition which may be used for the prophylactic and therapeutic treatment of a strep infection includes the lysin enzyme and a means of application (such as a carrier system or an oral delivery mode) to reach the mucosal lining of the oral and nasal cavity, such that the enzyme is put in the carrier system or oral delivery mode to reach the mucosa lining.
Another infection which can be treated prophylactically is Streptococcus group A, which can produce what is commonly known as “strep” throat. At the time this was taken, my urine pH was very low (acidic) and I was having a hard time bringing it up to alkaline for two days. The stabilizing buffer may also be or include a metal chelating reagent, such as ethylenediaminetetracetic acid disodium salt, or it may also contain a phosphate or citrate-phosphate buffer.Means of application include, but are not limited to direct, indirect, carrier and special means or any combination of means.
When I checked my skin I saw many more fibers then usual and many were still under the skin. Direct application of the lytic enzyme may be by nasal sprays, nasal drops, nasal ointments, nasal washes, nasal injections, nasal packings, bronchial sprays and inhalers, or indirectly through use of throat lozenges, or through use of mouthwashes or gargles, or through the use of ointments applied to the nasal nares, the bridge of the nose, or the face or any combination of these and similar methods of application.
I asked myself what would cause such fiber growth, and made the connection to an acidic system. The forms in which the lysin enzyme may be administered include but are not limited to lozenges, troches, candies, injectants, chewing gums, tablets, powders, sprays, liquids, ointments, and aerosols.The lozenge, tablet, or gum into which the lytic enzyme is added may contain sugar, corn syrup, a variety of dyes, non-sugar sweeteners, flavorings, any binders, or combinations thereof.
Similarly, any gum based products may contain acacia, carnauba wax, citric acid, corn starch, food colorings, flavorings, non-sugar sweeteners, gelatin, glucose, glycerin, gum base, shellac, sodium saccharin, sugar, water, white wax, cellulose, other binders, and combinations thereof.Lozenges may further contain sucrose, corn starch, acacia, gum tragacanth, anethole, linseed, oleoresin, mineral oil, and cellulose, other binders, and combinations thereof.
In another embodiment of the invention, sugar substitutes are used in place of dextrose, sucrose, or other sugars.The enzyme may also be placed in a nasal spray, wherein the nasal spray is the carrier.
It it my personal wish to see physicians actually begin to use magnification so that they may understand the phenomena their patients are experiencing.
The nasal spray can be a long acting or timed release spray, and can be manufactured by means well known in the art. An inhalant may also be used, so that the phage enzyme may reach further down into the bronchial tract, including into the lungs.Any of the carriers for the lytic enzyme may be manufactured by conventional means.
However, it is preferred that any mouthwash or similar type products not contain alcohol to prevent denaturing of the enzyme. Similarly, when the lytic enzyme is being placed in a cough drop, gum, candy or lozenge during the manufacturing process, such placement should be made prior to the hardening of the lozenge or candy but after the cough drop or candy has cooled somewhat, to avoid heat denaturation of the enzyme.The enzyme may be added to these substances in a liquid form or in a lyophilized state, whereupon it will be solubilized when it meets body fluids such as saliva.
Photo submitted courtesy of oddiyfuqoro NA will? Above: This particle is one of the classic forms I find being expelled from the body. The enzyme may also be in a micelle or liposome.The effective dosage rates or amounts of the lytic enzyme to treat the infection will depend in part on whether the lytic will be used therapeutically or prophylactically, the duration of exposure of the recipient to the infectious bacteria, the size and weight of the individual, etc.
Any dosage form employed should provide for a minimum number of units for a minimum amount of time. More specifically, time exposure to the active enzyme units may influence the desired concentration of active enzyme units per ml. It should be noted that carriers that are classified as “long” or “slow” release carriers (such as, for example, certain nasal sprays or lozenges) could possess or provide a lower concentration of active (enzyme) units per ml, but over a longer period of time, whereas a “short” or “fast” release carrier (such as, for example, a gargle) could possess or provide a high concentration of active (enzyme) units per ml, but over a shorter period of time. When using this composition for a Streptococcus A infection, the lysin phage enzyme should be used for the prophylactic prevention of Streptococcus infections. Similarly, in another embodiment of the invention, this method may be used for the therapeutic and, preferably, the prophylactic treatment of tuberculosis. In a preferred embodiment of the invention, the phage associated lysing enzyme for Mycobacteria tuberculosis is placed in a carrier in an inhaler. The carrier may be sterile water or a water base, or any other carrier used in an inhaler for dispersing drugs into the bronchial tract. The phage associated lytic enzyme specific for tuberculosis is subject to the same conditions as the phage associated lytic enzyme for other lytic enzymes.
The stabilizing buffer may also be or include a metal chelating reagent, such as ethylenediaminetetracetic acid disodium salt, or it may also contain a phosphate or citrate-phosphate buffer.For the prophylactic and therapeutic treatment of tuberculosis, the phage associated lytic enzyme associated with tuberculosis may also be applied by direct, indirect, carriers and special means or any combination of means. The forms in which the lytic enzyme may be administered include but are not limited to lozenges, troches, candies, injectants, chewing gums, tablets, powders, sprays, liquids, ointments, and aerosols. For the therapeutic treatment of tuberculosis, the bronchial sprays and aerosols are most beneficial, as these carriers, or means of distributing the composition, allow the lytic enzyme to reach the bronchial tubes and the lungs. An appropriate transport carrier may be attached to the enzyme to transport the enzyme across the cell membrane to the site of the bacteria.The lozenge, tablet, or gum into which the lytic enzyme is added may contain sugar, corn syrup, a variety of dyes, non-sugar sweeteners, flavorings, any binders, or combinations thereof. The Morgellons particles didn't match any of the 800 fibers on their database, nor the 85,000 known organic compounds.
For those insisting the CDC study of Morgellons laid down the law for definitive answers about Morgellons, I'd suggest you listen to Doctor Randy Wymore speak more in depth about the study and its inherent flaws and bias. However, to tackle bacterial infections in the lung, the use of an inhaler carrier the lytic enzyme in a carrier is preferred.Another use of a lytic enzyme is for the treatment of bacterial infections of the digestive tract. The method for treating a bacterial infection of the digestive tract comprises treating the bacterial infection with g composition comprising an effective amount of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for the bacteria, and a carrier for delivering said lytic enzyme to the digestive tract.
In a preferred embodiment of the invention, the bacterial infections being treated are being caused by gram negative bacteria selected from the group consisting of Listeria, Salmonella, E.
However, this method and composition will effectively treat other bacteria, when the appropriate lytic enzyme is used.In a preferred embodiment of the invention, the carrier is selected from the group consisting of suppository enemas, syrups, or enteric coated pills. However, the only difference in their manufacture is that the enzyme being placed in the carrier must not be allowed to denature. To that end, the enzyme should be incorporated into a carrier which does not contain alcohol, and which has been cooled to a temperature that will not cause the denaturing of the enzyme. The enzyme may be incorporated in a lyophilized state, or may be incorporated in a liposome before being placed in the suppository, syrup or enteric coated pill.The enzyme placed in the composition or carrier should be in an environment having a pH which allows for activity of the lytic enzyme. As described above with the other lytic enzyme, the pH can be moderated by the use of a buffer. The buffer may also be a a metal chelating reagent, such as ethylenediaminetetracetic disodium salt or the buffer may contain a citrate-phosphate buffer. As the suppository dissolves, the phage associated lytic enzyme will be released.Another composition and use of the lytic enzyme is for the therapeutic or prophylactic treatment of bacterial infections of burns and wounds of the skin.
The composition comprises an effective amount of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for the bacteria and a carrier for delivering at least one lytic enzyme to the wounded skin. The mode of application for the lytic enzyme includes a number of different types and combinations of carriers which include, but are not limited to an aqueous liquid, an alcohol base liquid, a water soluble gel, a lotion, an ointment, a nonaqueous liquid base, a mineral oil base, a blend of mineral oil and petrolatum, lanolin, liposomes, protein carriers such as serum albumin or gelatin, powdered cellulose carmel, and combinations thereof. A mode of delivery of the carrier containing the therapeutic agent includes but is not limited to a smear, spray, a time-release patch, a liquid absorbed wipe, and combinations thereof. The lytic enzyme may be applied to a bandage either directly or in one of the other carriers. The bandages may be sold damp or dry, wherein the enzyme is in a lyophilized form on the bandage. This method of application is most effective for the treatment of burns.The carriers of the compositions of the present invention may comprise semi-solid and gel-like vehicles that include a polymer thickener, water, preservatives, active surfactants or emulsifiers, antioxidants, sun screens, and a solvent or mixed solvent system.
5,863,560 (Osborne) discusses a number of different carrier combinations which can aid in the exposure of the skin to a medicament.Polymer thickeners that may be used include those known to one skilled in the art, such as hydrophilic and hydroalcoholic gelling agents frequently used in the cosmetic and pharmaceutical industries. Preferably, the gelling agent comprises between about 0.2% to about 4% by weight of the composition. These polymers dissolve in water and form a clear or slightly hazy gel upon neutralization with a caustic material such as sodium hydroxide, potassium hydroxide, triethanolamine, or other amine bases. Often the skin lesions and associated symptoms resolve once the above antibiotics are used in a comprehensive treatment plan" ??Horowitz, Richard (2013-11-12). The use of preservatives assures that if the product is microbially contaminated, the formulation will prevent or diminish microorganism growth. Some preservatives useful in this invention include methylparaben, propylparaben, butylparaben, chloroxylenol, sodium benzoate, DMDM Hydantoin, 3-Iodo-2-Propylbutyl carbamate, potassium sorbate, chlorhexidine digluconate, or a combination thereof.Titanium dioxide may be used as a sunscreen to serve as prophylaxis against photosensitization.
An alternate antioxidant is BHT.Pharmaceuticals for use in all embodiments of the invention include antimicrobial agents, anti-inflammatory agents, antiviral agents, local anesthetic agents, corticosteroids, destructive therapy agents, antifungals, and antiandrogens. In the treatment of acne, active pharmaceuticals that may be used include antimicrobial agents, especially those having anti-inflammatory properties such as dapsone, erythromycin, minocycline, tetracycline, clindamycin, and other antimicrobials. A preferred concentration for local anesthetics is about 0.025% to 5% by weight of the total composition. Another example is the use of minoxidil in combination with a corticosteroid such as betamethasone diproprionate for the treatment of alopecia ereata.

How to get rid of gas smell in the house
How to treat serous conjunctivitis in dogs 101
Treatment to get rid of acne marks
22.05.2014, author: admin

Comments to «Treating bacterial eye infections episcleritis»

  1. shirin writes:
    And skin-to-pores and skin contact, you pap take a look at?�that may find.
  2. Ilqar_Vasmoylu writes:
    This nonsense ??but when you've.